Gamma Knife Market Size, Share & Trends Analysis Report By Indication (Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders, Ocular Diseases), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global gamma knife market size was valued at USD 364.6 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5.0% from 2022 to 2030. The increasing prevalence of neurological disorders and brain tumors, rapid adoption of gamma knife surgeries as an effective treatment option, continuous technological advancements, and evolution of minimally invasive surgery options are expected to fuel the market growth. However, higher costs of treatments and installation of machinery, fluctuating reimbursement rates, and a dearth of skilled professionals are factors expected to hamper the market growth.

The COVID-19 pandemic has negatively impacted radiology practices across the globe. A 50% reduction in elective surgeries was witnessed within the first month of the pandemic. Hospitals are mainly focusing on tackling COVID-19 cases, which minimized their capacity to undertake critical radiotherapy operations. Reduction in raw material production, halt in logistics, reduced sales of newer systems, and national lockdowns were other reasons for the drop in market size in 2020.

The global burden of neurological disorders is measured by the absolute number of Disability-adjusted Life Years (DALYs), which continues to increase. The prevalence of major neurological disorders is increasing owing to the rising geriatric population. According to the American Cancer Society, brain tumor is considered the 8th most common type of cancer and the 3rd most common cause of cancer deaths in the age group of 40 and above. As the population is aging and growing, the demand for treatment and rehabilitation for neurological diseases is expected to increase significantly, hence positively impacting the growth of the market.

Gamma knife surgery is a computer-guided treatment, which is painless and used to deliver strong focused radiation beams to treat brain tumors and lesions, arteriovenous malformations, acoustic neuroma, tremors, and trigeminal neuralgia. For instance, Leksell Gamma Knife Icon, by a key market player Elekta AB (publ), uses single or fractionated frame-based or frameless treatments with more precision and accuracy for brain tumors, cancer, and other neurological diseases.

Indication Insights

The malignant tumors segment held the largest revenue share of over 45.0% in 2021. The benign tumors segment is expected to grow over the forecast period owing to the increasing prevalence of meningioma. On the basis of indication, the market is segmented into malignant tumors, benign tumors, vascular disorders, functional disorders, and ocular brain tumors.

According to the American Society of Clinical Oncology (ASCO), currently, 700,000 patients are suffering from brain tumors. In 2021, around 24,530 adults-13,840 males and 10,690 females in the U.S. are expected to be diagnosed with the primary type of malignant tumor in the spinal cord and brain. In addition, around 3,460 children under the age of 15 years are expected to be diagnosed with brain tumors. Around 18,600 adults-around 10,500 males and 8,100 females-are likely to die due to these types of cancer in the coming year, thereby augmenting the segment growth.

Regional Insights

In 2021, Asia Pacific held the largest revenue share of over 35.0%. An increase in the prevalence of neurological diseases, a rise in healthcare expenditures, and growth in the accessibility of gamma knife surgeries are some of the key factors expected to drive the market in APAC over the forecast period.

The adoption of gamma knife surgery systems is reported to be increasing in North America. Moreover, various clinical studies are being undertaken for exploring the applications of gamma knife radiotherapy in treating essential tremors, such as Parkinson’s and glioblastoma. Thus, the expansion of applications of gamma knife radiotherapy to other treatment areas is expected to further drive the market.

Key Companies & Market Share Insights

Key market players operating in the market are involved in novel product launches, joint ventures, product innovation, collaboration and partnerships, and mergers & acquisitions to expand their global reach. For instance, in May 2020, Elekta launched Leksell Gamma Knife Lightning, which was the only fully integrated automated treatment planning solution for gamma knives that enables plan-optimization based on parameters such as beam on-time constraints. Some prominent players in the global gamma knife market include:

• Elekta AB

• Varian Medical Systems

• Huiheng Medical, Inc.

• MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.

• Akesis Inc.

Gamma Knife Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global gamma knife market report based on indication and region:

• Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Malignant Tumors

  • Benign Tumors

  • Vascular Disorders

  • Functional Disorders

  • Ocular Diseases

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE